))
Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders
Manage episode 417617266 series 3554501
Content provided by Teymour Boutros-Ghali and Felicia Hsu, Teymour Boutros-Ghali, and Felicia Hsu. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Teymour Boutros-Ghali and Felicia Hsu, Teymour Boutros-Ghali, and Felicia Hsu or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.
Story Notes:
- Addressing the Obesity Challenge
- Navigating the Regulatory Landscape
- The Potential Impact on the Pharmaceutical Industry
To learn more, visit:
https://boldcapitalpartners.com/
4 episodes
Share
